Stock Market Reviews

LENZ (LENZ Therapeutics, Inc.) News

Get the latest news, insights, and market updates on LENZ (LENZ Therapeutics, Inc.). Explore the news page 2 on MyTopStock.com for investor discussions, analysis, and real-time stock performance coverage.

• LENZ Therapeutics, Inc. (LENZ) Upgraded to Buy: What Does It Mean for the Stock?
  LENZ Therapeutics, Inc. (LENZ) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).
  Oct 22, 2025 - $LENZ
• Companies Like LENZ Therapeutics (NASDAQ:LENZ) Can Afford To Invest In Growth
  We can readily understand why investors are attracted to unprofitable companies. For example, LENZ Therapeutics...
  Oct 1, 2025 - $LENZ
• LENZ Therapeutics Announces Commercial Product Availability of VIZZ™ in the United States
  LENZ Therapeutics, Inc. (Nasdaq: LENZ or "LENZ" or the "Company"), today announced VIZZ (aceclidine ophthalmic solution) 1.44%, the first and only FDA-approved aceclidine-based eye drop for the treatment of presbyopia in adults, is now available. Professional product sample distribution by the sales force to optometrists and ophthalmologists has been initiated nationwide. Commercial product shipments will be initiated to consumers in October through our ePharmacy partner and is anticipated to be
  Sep 30, 2025 - $LENZ
• Staar Surgical, Insight Enterprises, and More Stocks See Action From Activist Investors
  13D FILINGS These disclosures are from 13Ds filed with the Securities and Exchange Commission. 13Ds are filed within 10 days of an entity’s attaining more than 5% in any class of a company’s securities.
  Sep 26, 2025 - $LENZ
• Jim Cramer Says “LENZ Therapeutics Has a Promising Story”
  LENZ Therapeutics, Inc. (NASDAQ:LENZ) is one of the stocks Jim Cramer recently gave takes on. Commenting on the company’s eyedrops, VIZZ, Cramer said: “Overall, I’m inclined to believe that there’ll be enough patients eager to try the product. We’re talking a total addressable market of 128 million people. You don’t need to get that many […]
  Sep 22, 2025 - $LENZ
• Core Scientific, NewAmsterdam Pharma, and More Stocks See Action From Activist Investors
  13D FILINGS These disclosures are from 13Ds filed with the Securities and Exchange Commission. 13Ds are filed within 10 days of an entity’s attaining more than 5% in any class of a company’s securities.
  Aug 29, 2025 - $LENZ
• LENZ Therapeutics to Present at Upcoming Investor and Medical Conferences
  SAN DIEGO, Aug. 25, 2025 (GLOBE NEWSWIRE) -- LENZ Therapeutics, Inc. (Nasdaq: LENZ or “LENZ” or the “Company”), a pharmaceutical company focused on the commercialization of VIZZ™ (aceclidine ophthalmologic solution) 1.44%, the first and only FDA-approved aceclidine-based eye drop for the treatment of presbyopia in adults, today announced that company management will participate in the following upcoming investor and medical conferences, including presentations featuring VIZZ at Academy 2025 pres
  Aug 25, 2025 - $LENZ
• Will FDA Approval of Vizz Eye Drops Change LENZ Therapeutics' (LENZ) Narrative?
  LENZ Therapeutics recently received FDA approval for its Vizz eye drops to treat presbyopia in adults, offering a new non-surgical solution for age-related farsightedness. This regulatory milestone positions LENZ Therapeutics for significant commercial potential as one of the first entrants in this therapeutic category. We’ll examine how the early FDA approval of Vizz could reshape LENZ Therapeutics’ investment narrative and future market approach. Explore 24 top quantum computing companies...
  Aug 21, 2025 - $LENZ
• LENZ Therapeutics Announces US FDA Approval of VIZZ™ for the Treatment of Presbyopia
  VIZZ is the first and only aceclidine-based eye drop approved to improve near vision in adults with presbyopia, a condition impacting approximately 128 million adults in the United States First once daily solution to treat blurry near vision with proven efficacy for up to 10 hours VIZZ samples and product availability in the United States expected as early as October 2025 Conference call and webcast to be held August 1, 2025 at 8:00 a.m. EDT SAN DIEGO, July 31, 2025 (GLOBE NEWSWIRE) -- LENZ Ther
  Jul 31, 2025 - $LENZ
• LENZ Therapeutics, Inc. (LENZ) Reports Q2 Loss
  LENZ Therapeutics, Inc. (LENZ) delivered earnings and revenue surprises of +8.62% and 0.00%, respectively, for the quarter ended June 2025. Do the numbers hold clues to what lies ahead for the stock?
  Jul 30, 2025 - $LENZ